← Leaderboards
Richard N Greenberg
University Of Kentucky
$346,784
Attributed
$346,784
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$346,784 · 5
By mechanism
M01$346,784 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Kentucky
Same institution · by research overlap
- Michal J. Toborek$37,025,871
- Joseph R Berger$2,809,271
- Eric J Smart$7,768,410
- Malcolm J Avison$6,414,826
- Marcelo Kugelmas$73,667
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationHiv InfectionsHuman SubjectClinical ResearchAids TherapyIndinavirCombination ChemotherapyAidsDrug Screening /EvaluationLamivudineAntiviral AgentsAntiaids AgentNelfinavirNucleoside AnalogOutcomes ResearchPharmacokineticsSaquinavirVirus LoadWomen'S HealthFemaleZidovudineEfavirenzCervix Disorder
Grant awards (15)
ACTG 866 WOMENS STUDY OF PROT ACTG 320 INDINAVIR &LAMIVUDINE$73,467
M01 · FY2002 · RR
PHASE II STUDY OF 1592U89 &INDINAVIR IN HIV (ACTG368)$73,467
M01 · FY2002 · RR
ACTG 372--INDINAVIR IN COMBINATION IN HIV INFECTED PTS$0
M01 · FY2002 · RR
ACTG 388--TRIAL OF EFAVIRENZ OR NELFINAVIR IN HIV PTS$0
M01 · FY2002 · RR
PHASE IV FORTOVASE IN COMBINATION IN HIV$0
M01 · FY2002 · RR
ACTG 866 WOMENS STUDY OF PROT ACTG 320 INDINAVIR &LAMIVUDINE$73,467
M01 · FY2001 · RR
PHASE II STUDY OF 1592U89 &INDINAVIR IN HIV (ACTG368)$73,467
M01 · FY2001 · RR
ACTG 388--TRIAL OF EFAVIRENZ OR NELFINAVIR IN HIV PTS$0
M01 · FY2001 · RR
ACTG 372--INDINAVIR IN COMBINATION IN HIV INFECTED PTS$0
M01 · FY2001 · RR
PHASE IV FORTOVASE IN COMBINATION IN HIV$0
M01 · FY2001 · RR
ACTG 866 WOMENS STUDY OF PROT ACTG 320 INDINAVIR &LAMIVUDINE$26,458
M01 · FY2000 · RR
PHASE II STUDY OF 1592U89 &INDINAVIR IN HIV (ACTG368)$26,458
M01 · FY2000 · RR
PHASE IV FORTOVASE IN COMBINATION IN HIV$0
M01 · FY2000 · RR
ACTG 372--INDINAVIR IN COMBINATION IN HIV INFECTED PTS$0
M01 · FY2000 · RR
ACTG 388--TRIAL OF EFAVIRENZ OR NELFINAVIR IN HIV PTS$0
M01 · FY2000 · RR